FHIR Implementation Guide for HCX - Local Development build (v0.7.0). See the Directory of published versions
@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
# - resource -------------------------------------------------------------------
a fhir:ValueSet;
fhir:nodeRole fhir:treeRoot;
fhir:Resource.id [ fhir:value "informational-messages-codes"];
fhir:DomainResource.text [
fhir:Narrative.status [ fhir:value "generated" ];
fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This value set contains 136 concepts</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>System</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MG045A\"> </a> MG045A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Dialysis payable separately as an add on package</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MG072A\"> </a> MG072A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Package cost of one session</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MG075A\"> </a> MG075A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Rs. 5000 is the upper limit.\nCan be booked at a lower rate also.\nIn fact the SHA should examine this package and confirm wheter the package has been booked at the usual market rate.\nCan be booked for a pt. already admitted under any medical package.</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO014F\"> </a> MO014F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and adjuvant rectal cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO062A1\"> </a> MO062A1</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>ACUTE LYMPHOBLASTIC LEUKEMIA</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MR001A\"> </a> MR001A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SB030A\"> </a> SB030A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Can be used for ORIF, wherever indicated.\nCan not be used as an Add - on package</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SB032A\"> </a> SB032A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis\nType V & VI to be taken up for Surgery straight away\nIn case Type I or II is booked a Pop Up to be shown "For Rockwood Type I & II - AC Joint injury, experts recommend Medical Management, are you sure you want to do Surgical Correction in this case ?" \nFor Hospitals booking Surgical Correction in Type I & Type II cases, Medical Audit will be conducted.</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SB032C\"> </a> SB032C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis\nType V & VI to be taken up for Surgery straight away</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SB070A\"> </a> SB070A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>LA for - K Wire & Screw\nGA for - Nail & Plate</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SC076A\"> </a> SC076A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>If the Hospital choses Pediatric Port in a pt. aged more than 14 years. Then it should be audited</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE012A\"> </a> SE012A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>The package is inclusive of Eye Bank processing fee</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE012B\"> </a> SE012B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>This is a special follow up package, as in Corneal graft surgery, a follow up at 1 week is required.\nAt this time, the surgeon has to examine and then prescribe medicine for next one month.\nThe medicine for 1 month has to be given at the time of booking this package.\nA signed reciept from the pt. is an essential document</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE018A\"> </a> SE018A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>To be done only after a prior scleral buckling surgery history</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE022A\"> </a> SE022A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Can be booked only after 1 year of cataract surgery</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE025A\"> </a> SE025A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Can be booked as a complication of cataract surgery atleast 15 days after discharge</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE029A\"> </a> SE029A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>The procedure is done only once per eye and not repeated</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE029B\"> </a> SE029B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>1. Claim to be raised after all 3 sittings have been done per eye.\n2. The interval between subsequent sittings is atleast 1 week.</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE033A\"> </a> SE033A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Pre-auth to be raised only in cases which have a prior history of Vitreoretinal surgery done atleast 3 months ago</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SG097A\"> </a> SG097A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Can be booked only after 15 days of Ileostomy and then every 2 months thereafter till the closure of stoma.\nThe Hospital has to upload a signed statement from pt. that s/he has received the cosnumables: Ileostomy - bags, adhesive, clips etc for 2 months</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SG097B\"> </a> SG097B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Can be booked only after 15 days of Colostomy and then every 2 months thereafter till the closure of stoma.\nThe Hospital has to upload a signed statement from pt. that s/he has received the cosnumables: colostomy - bags, adhesive, clips etc for 2 months</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SU052A\"> </a> SU052A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Payment to be made after completion of one month.</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SU060A\"> </a> SU060A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Claim to be raised after 6th Cycle</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SU060B\"> </a> SU060B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Claim for Rs. 15,000 can be raised after 6th Cycle.\nRemainaing Rs. 15,000 can be claimed after 12th Cycle</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SU071C\"> </a> SU071C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>No payment to be done to the Hospital for this stage\nThe package can be booked only if the first stage package has been booked prior to this</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SU071D\"> </a> SU071D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>The package can be booked only if the first stage and / or intermediate stage package has been booked prior to this</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SV032A\"> </a> SV032A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Associated with CABG\nNeed to submit Barcode/ ID number of IABP. Intra-operative use of IABP as a part of operative strategy, not included\nIncidence - 5% to 7%\nScrutiny of Hospitals where incidence is more than twice of prescribed limit</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001A\"> </a> MO001A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy in breast cancer\nMetastatic breast cancer\n(should not have received the same regimen or AC earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001B\"> </a> MO001B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy after 4 cycles of AC or EC</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001C\"> </a> MO001C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metstatic breast cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001D\"> </a> MO001D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy in breast cancer with cardiac dysfunction or not suitable for anthracycline based therapy\nMetstatic breast cancer\n(should not have received the same regimen earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001E\"> </a> MO001E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy in breast cancer with cardiac dysfunction or not suitable for anthracycline based therapy and high nodal burden\nMetastatic breast cancer\n(should not have received the same regimen earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001F\"> </a> MO001F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy in breast cancer with Her-2 neu positive patients</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001G\"> </a> MO001G</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant or neoadjuvant therapy in ER / PR psotive breast cancer\nER / PR positive metastatic breast cancer\n(if not receive earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001H\"> </a> MO001H</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant or neoadjuvant therapy in ER / PR psotive breast cancer\nER / PR positive metastatic breast cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001I\"> </a> MO001I</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant or neoadjuvant therapy breast cancer\nmetastatic breast cancer\n(if not received earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001L\"> </a> MO001L</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy in breast cancer\nMetstatic breast cancer\n(should not have received the same regimen or EC earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001M\"> </a> MO001M</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic breast cancer ER / PR positive</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001N\"> </a> MO001N</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant or neoadjuvant therapy breast cancer\nmetastatic breast cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001O\"> </a> MO001O</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic breast cancer ER / PR positive</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO002A\"> </a> MO002A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic bone malignancy and multiple myeloma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO003A\"> </a> MO003A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic ovarian adenocarcinoma second line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO003B\"> </a> MO003B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant and metastatic ovarian adenocarcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO004A\"> </a> MO004A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Testicular Seminoma, Adjuvant</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO004B\"> </a> MO004B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Germ cell tumour of any site for Neoadjuvant, adjuvant or metastatic first line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO004D\"> </a> MO004D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Germ cell tumour second line therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO005A\"> </a> MO005A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>First line therapy for high - risk Gestational Trophoblastic Neoplasia\nSecond line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO005C\"> </a> MO005C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>First line therapy for low risk Gestational Trophoblastic Neoplasia</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO006A\"> </a> MO006A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and metastatic Cervical Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO006B\"> </a> MO006B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Stage II and Stage III cervical cancer definitive therapy along with Radiation therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO007A\"> </a> MO007A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Adjuvant and Metastatic Endometrial Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO007B\"> </a> MO007B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Endometrial Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO008A\"> </a> MO008A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>NACT, mets</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO008B\"> </a> MO008B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Stage II and Stage III cervical cancer definitive therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO009A\"> </a> MO009A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Ewing Sarcoma second line chemotherapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO010A\"> </a> MO010A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Osteogenic carcinoma Neoadjuvant and adjuvant therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO010B\"> </a> MO010B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Relapsed Osteogenic Sarcoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO010C\"> </a> MO010C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Osteogenic carcinoma Neoadjuvant therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO010D\"> </a> MO010D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Osteogenic carcinoma adjuvant therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO011A\"> </a> MO011A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>NACT, Adjuvant, mets (if cardiac dysfunction)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO011B\"> </a> MO011B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Soft tissue sarcoma neoadjuvant, adjuvant and metastatic</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO012A\"> </a> MO012A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Melanoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO013A\"> </a> MO013A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Stage II and III anal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO013C\"> </a> MO013C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Anal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO014A\"> </a> MO014A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant and Metastatic Colorectal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO014B\"> </a> MO014B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Colorectal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO014H\"> </a> MO014H</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and adjuvant Colorectal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO015A\"> </a> MO015A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and adjuvant esophageal cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO015B\"> </a> MO015B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Upper esophageal neoadjuvant and with RT as adjuvant</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO015D\"> </a> MO015D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>With RT in definitive non-metastatic</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO015E\"> </a> MO015E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic without RT</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016B\"> </a> MO016B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic second line esophageal and stomach cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016C\"> </a> MO016C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Till RT ends\nLower esophageal and stomach Cancer with RT as adjuvant</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016D\"> </a> MO016D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Till completion of RT\nLower esophageal and stomach Cancer with RT as adjuvant</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016E\"> </a> MO016E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant and Metastatic Stomach, Lower esophageal (adenocarcinoma) cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016F\"> </a> MO016F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant and metastatic stomach and lower esophageal (adenocarcinoma) cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016J\"> </a> MO016J</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metatstaic lower esophageal and stomach Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016K\"> </a> MO016K</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant for stomach and lower esophageal (adenocarcinoma) cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016L\"> </a> MO016L</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant, along with Radiation (concurrent), metastatic esophageal cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO017A\"> </a> MO017A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Liver confined hepatocellular carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO017B\"> </a> MO017B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Meatastatic hepatocellular carcinoma (except child Pugh c)\nLiver confined but not suitable for liver directed therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO018B\"> </a> MO018B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic pancreatic cancer - first line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO018C\"> </a> MO018C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and adjuvant locally advanced pancreatic cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO018E\"> </a> MO018E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Till RT ends\nNeoadjuvant and adjuvant locally advanced pancreatic cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO018F\"> </a> MO018F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Pancreatic cancer - adjuvant</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019A\"> </a> MO019A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant and metastatic gall bladder and cholnagicarcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019B\"> </a> MO019B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant and metastatic pancreatic cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019C\"> </a> MO019C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic gall bladder and cholngiocarcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019D\"> </a> MO019D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Till RT ends\nDefinitive and Adjuvant therapy in gall bladder cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019E\"> </a> MO019E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metatstatic Gall Bladder Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO020A\"> </a> MO020A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant and metastatic GIST</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO020B\"> </a> MO020B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic GIST</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO021A\"> </a> MO021A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO022A\"> </a> MO022A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic mesothelioma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO022B\"> </a> MO022B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant,adjuvant and metastatic mesothelioma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO023A\"> </a> MO023A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant Chemotherapy and metastatic thymic carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024A\"> </a> MO024A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and metastatic head and neck squamou cell cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024B\"> </a> MO024B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Definitive therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024C\"> </a> MO024C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic squamous cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024D\"> </a> MO024D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Metastatic squamou cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024E\"> </a> MO024E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic squamou cell head and neck cancer, salivary gland cancers</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024F\"> </a> MO024F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Head and neck squamous cell carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024G\"> </a> MO024G</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant and metastatic esthesioneuroblastoma and Neuroendocrine carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024L\"> </a> MO024L</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic squamous cell head and neck cancer, salivary gland cancers, nasopharyngeal carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024M\"> </a> MO024M</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic squamous cell head and neck cancer, salivary gland cancers</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO025A\"> </a> MO025A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic renal cell carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO026A\"> </a> MO026A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Metastatic urothelial cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO026B\"> </a> MO026B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Adjuvant, Metastatic urothelial cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO026F\"> </a> MO026F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic urothelial cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO027A\"> </a> MO027A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Adjuvant, Metastatic penile cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO027C\"> </a> MO027C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Penile Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO028A\"> </a> MO028A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic prostate cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO033A\"> </a> MO033A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Multiagent chemotherapy variable in each protocol</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO047C\"> </a> MO047C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Optional Vincristine and Prednsiolone\nIntrathecal Methotrexate</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO048C\"> </a> MO048C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Optional Vincristine and Prednsiolone, intrathecal Methotrexate</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO054A\"> </a> MO054A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Histiocytosis Protocol - Induction</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO054B\"> </a> MO054B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Histiocytosis Protocol - Maintenance</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO055A\"> </a> MO055A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Low Grade Glioma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO056A\"> </a> MO056A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Medulloblastoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO057A\"> </a> MO057A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neuroblastoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO058A\"> </a> MO058A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Retinoblastoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO059A\"> </a> MO059A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Rhabdomyosarcoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO060A\"> </a> MO060A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Relapsed Rhabdomyosarcoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO062A\"> </a> MO062A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Phase II, CNS Therapy Reinduction</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO066A\"> </a> MO066A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Relapsed Hodgkins Lymphoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO066B\"> </a> MO066B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Hodgkins Lymphoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO068A\"> </a> MO068A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Non - Hodgkins Lymphoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071A\"> </a> MO071A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metstatic non small cell lung cancer - second line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071E\"> </a> MO071E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic non small cell lung (adenocarcinoma) cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071F\"> </a> MO071F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic small cell lung cancer - second line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071G\"> </a> MO071G</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Non Small Cell Lung Cancer - in patients unfit for combination therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071H\"> </a> MO071H</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, concurrent with radiation and metastaic small cell lung cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071K\"> </a> MO071K</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and Metastatic Non Small Cell Lung cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071O\"> </a> MO071O</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Concurrent chemoradiation in Non Small Cell lung cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071Q\"> </a> MO071Q</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Adjuvant and Metastatic Non Small Cell Lung cancer (adnocarcinoma and adenosquamous carcinoma)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071R\"> </a> MO071R</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic non small cell lung cancer (adenocarcinoma) as maintenance after\nCarboplatin + Pemetrexed and\nCisplatin + Pemetrexed 4 -6 cycles</td></tr></table></div>"
];
fhir:ValueSet.url [ fhir:value "https://ig.hcxprotocol.io/v0.7/ValueSet-informational-messages-codes.html"];
fhir:ValueSet.version [ fhir:value "0.7.0"];
fhir:ValueSet.name [ fhir:value "InformationalMessagesCodes"];
fhir:ValueSet.status [ fhir:value "active"];
fhir:ValueSet.date [ fhir:value "2022-06-01"^^xsd:date];
fhir:ValueSet.publisher [ fhir:value "HCX Open Community"];
fhir:ValueSet.contact [
fhir:index 0;
fhir:ContactDetail.name [ fhir:value "HCX Open Community" ];
fhir:ContactDetail.telecom [
fhir:index 0;
fhir:ContactPoint.system [ fhir:value "url" ];
fhir:ContactPoint.value [ fhir:value "http://hcxprotocol.io/" ] ]
];
fhir:ValueSet.description [ fhir:value "This is the value set that includes the informational messages codes"];
fhir:ValueSet.expansion [
fhir:ValueSet.expansion.timestamp [ fhir:value "2022-06-01T08:15:30+05:30"^^xsd:dateTime ];
fhir:ValueSet.expansion.contains [
fhir:index 0;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MG045A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Dialysis payable separately as an add on package" ] ], [
fhir:index 1;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MG072A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Package cost of one session" ] ], [
fhir:index 2;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MG075A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Rs. 5000 is the upper limit.\nCan be booked at a lower rate also.\nIn fact the SHA should examine this package and confirm wheter the package has been booked at the usual market rate.\nCan be booked for a pt. already admitted under any medical package." ] ], [
fhir:index 3;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO014F" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant and adjuvant rectal cancer" ] ], [
fhir:index 4;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO062A1" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "ACUTE LYMPHOBLASTIC LEUKEMIA" ] ], [
fhir:index 5;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MR001A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`" ] ], [
fhir:index 6;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SB030A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Can be used for ORIF, wherever indicated.\nCan not be used as an Add - on package" ] ], [
fhir:index 7;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SB032A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis\nType V & VI to be taken up for Surgery straight away\nIn case Type I or II is booked a Pop Up to be shown \"For Rockwood Type I & II - AC Joint injury, experts recommend Medical Management, are you sure you want to do Surgical Correction in this case ?\" \nFor Hospitals booking Surgical Correction in Type I & Type II cases, Medical Audit will be conducted." ] ], [
fhir:index 8;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SB032C" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis\nType V & VI to be taken up for Surgery straight away" ] ], [
fhir:index 9;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SB070A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "LA for - K Wire & Screw\nGA for - Nail & Plate" ] ], [
fhir:index 10;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SC076A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "If the Hospital choses Pediatric Port in a pt. aged more than 14 years. Then it should be audited" ] ], [
fhir:index 11;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SE012A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "The package is inclusive of Eye Bank processing fee" ] ], [
fhir:index 12;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SE012B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "This is a special follow up package, as in Corneal graft surgery, a follow up at 1 week is required.\nAt this time, the surgeon has to examine and then prescribe medicine for next one month.\nThe medicine for 1 month has to be given at the time of booking this package.\nA signed reciept from the pt. is an essential document" ] ], [
fhir:index 13;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SE018A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "To be done only after a prior scleral buckling surgery history" ] ], [
fhir:index 14;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SE022A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Can be booked only after 1 year of cataract surgery" ] ], [
fhir:index 15;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SE025A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Can be booked as a complication of cataract surgery atleast 15 days after discharge" ] ], [
fhir:index 16;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SE029A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "The procedure is done only once per eye and not repeated" ] ], [
fhir:index 17;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SE029B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "1. Claim to be raised after all 3 sittings have been done per eye.\n2. The interval between subsequent sittings is atleast 1 week." ] ], [
fhir:index 18;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SE033A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Pre-auth to be raised only in cases which have a prior history of Vitreoretinal surgery done atleast 3 months ago" ] ], [
fhir:index 19;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SG097A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Can be booked only after 15 days of Ileostomy and then every 2 months thereafter till the closure of stoma.\nThe Hospital has to upload a signed statement from pt. that s/he has received the cosnumables: Ileostomy - bags, adhesive, clips etc for 2 months" ] ], [
fhir:index 20;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SG097B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Can be booked only after 15 days of Colostomy and then every 2 months thereafter till the closure of stoma.\nThe Hospital has to upload a signed statement from pt. that s/he has received the cosnumables: colostomy - bags, adhesive, clips etc for 2 months" ] ], [
fhir:index 21;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SU052A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Payment to be made after completion of one month." ] ], [
fhir:index 22;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SU060A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Claim to be raised after 6th Cycle" ] ], [
fhir:index 23;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SU060B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Claim for Rs. 15,000 can be raised after 6th Cycle.\nRemainaing Rs. 15,000 can be claimed after 12th Cycle" ] ], [
fhir:index 24;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SU071C" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "No payment to be done to the Hospital for this stage\nThe package can be booked only if the first stage package has been booked prior to this" ] ], [
fhir:index 25;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SU071D" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "The package can be booked only if the first stage and / or intermediate stage package has been booked prior to this" ] ], [
fhir:index 26;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "SV032A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Associated with CABG\nNeed to submit Barcode/ ID number of IABP. Intra-operative use of IABP as a part of operative strategy, not included\nIncidence - 5% to 7%\nScrutiny of Hospitals where incidence is more than twice of prescribed limit" ] ], [
fhir:index 27;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO001A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Adjuvant therapy in breast cancer\nMetastatic breast cancer\n(should not have received the same regimen or AC earlier)" ] ], [
fhir:index 28;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO001B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Adjuvant therapy after 4 cycles of AC or EC" ] ], [
fhir:index 29;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO001C" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metstatic breast cancer" ] ], [
fhir:index 30;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO001D" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Adjuvant therapy in breast cancer with cardiac dysfunction or not suitable for anthracycline based therapy\nMetstatic breast cancer\n(should not have received the same regimen earlier)" ] ], [
fhir:index 31;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO001E" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Adjuvant therapy in breast cancer with cardiac dysfunction or not suitable for anthracycline based therapy and high nodal burden\nMetastatic breast cancer\n(should not have received the same regimen earlier)" ] ], [
fhir:index 32;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO001F" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Adjuvant therapy in breast cancer with Her-2 neu positive patients" ] ], [
fhir:index 33;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO001G" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Adjuvant or neoadjuvant therapy in ER / PR psotive breast cancer\nER / PR positive metastatic breast cancer\n(if not receive earlier)" ] ], [
fhir:index 34;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO001H" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Adjuvant or neoadjuvant therapy in ER / PR psotive breast cancer\nER / PR positive metastatic breast cancer" ] ], [
fhir:index 35;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO001I" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Adjuvant or neoadjuvant therapy breast cancer\nmetastatic breast cancer\n(if not received earlier)" ] ], [
fhir:index 36;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO001L" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Adjuvant therapy in breast cancer\nMetstatic breast cancer\n(should not have received the same regimen or EC earlier)" ] ], [
fhir:index 37;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO001M" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic breast cancer ER / PR positive" ] ], [
fhir:index 38;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO001N" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Adjuvant or neoadjuvant therapy breast cancer\nmetastatic breast cancer" ] ], [
fhir:index 39;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO001O" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic breast cancer ER / PR positive" ] ], [
fhir:index 40;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO002A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic bone malignancy and multiple myeloma" ] ], [
fhir:index 41;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO003A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic ovarian adenocarcinoma second line" ] ], [
fhir:index 42;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO003B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant, adjuvant and metastatic ovarian adenocarcinoma" ] ], [
fhir:index 43;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO004A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Testicular Seminoma, Adjuvant" ] ], [
fhir:index 44;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO004B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Germ cell tumour of any site for Neoadjuvant, adjuvant or metastatic first line" ] ], [
fhir:index 45;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO004D" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Germ cell tumour second line therapy" ] ], [
fhir:index 46;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO005A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "First line therapy for high - risk Gestational Trophoblastic Neoplasia\nSecond line" ] ], [
fhir:index 47;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO005C" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "First line therapy for low risk Gestational Trophoblastic Neoplasia" ] ], [
fhir:index 48;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO006A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant and metastatic Cervical Cancer" ] ], [
fhir:index 49;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO006B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Stage II and Stage III cervical cancer definitive therapy along with Radiation therapy" ] ], [
fhir:index 50;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO007A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant, Adjuvant and Metastatic Endometrial Cancer" ] ], [
fhir:index 51;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO007B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic Endometrial Cancer" ] ], [
fhir:index 52;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO008A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "NACT, mets" ] ], [
fhir:index 53;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO008B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Stage II and Stage III cervical cancer definitive therapy" ] ], [
fhir:index 54;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO009A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Ewing Sarcoma second line chemotherapy" ] ], [
fhir:index 55;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO010A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Osteogenic carcinoma Neoadjuvant and adjuvant therapy" ] ], [
fhir:index 56;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO010B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Relapsed Osteogenic Sarcoma" ] ], [
fhir:index 57;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO010C" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Osteogenic carcinoma Neoadjuvant therapy" ] ], [
fhir:index 58;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO010D" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Osteogenic carcinoma adjuvant therapy" ] ], [
fhir:index 59;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO011A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "NACT, Adjuvant, mets (if cardiac dysfunction)" ] ], [
fhir:index 60;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO011B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Soft tissue sarcoma neoadjuvant, adjuvant and metastatic" ] ], [
fhir:index 61;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO012A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic Melanoma" ] ], [
fhir:index 62;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO013A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Stage II and III anal Cancer" ] ], [
fhir:index 63;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO013C" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic Anal Cancer" ] ], [
fhir:index 64;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO014A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Adjuvant and Metastatic Colorectal Cancer" ] ], [
fhir:index 65;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO014B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic Colorectal Cancer" ] ], [
fhir:index 66;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO014H" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant and adjuvant Colorectal Cancer" ] ], [
fhir:index 67;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO015A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant and adjuvant esophageal cancer" ] ], [
fhir:index 68;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO015B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Upper esophageal neoadjuvant and with RT as adjuvant" ] ], [
fhir:index 69;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO015D" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "With RT in definitive non-metastatic" ] ], [
fhir:index 70;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO015E" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic without RT" ] ], [
fhir:index 71;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO016B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic second line esophageal and stomach cancer" ] ], [
fhir:index 72;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO016C" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Till RT ends\nLower esophageal and stomach Cancer with RT as adjuvant" ] ], [
fhir:index 73;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO016D" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Till completion of RT\nLower esophageal and stomach Cancer with RT as adjuvant" ] ], [
fhir:index 74;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO016E" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Adjuvant and Metastatic Stomach, Lower esophageal (adenocarcinoma) cancer" ] ], [
fhir:index 75;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO016F" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant, adjuvant and metastatic stomach and lower esophageal (adenocarcinoma) cancer" ] ], [
fhir:index 76;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO016J" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metatstaic lower esophageal and stomach Cancer" ] ], [
fhir:index 77;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO016K" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Adjuvant for stomach and lower esophageal (adenocarcinoma) cancer" ] ], [
fhir:index 78;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO016L" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant, adjuvant, along with Radiation (concurrent), metastatic esophageal cancer" ] ], [
fhir:index 79;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO017A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Liver confined hepatocellular carcinoma" ] ], [
fhir:index 80;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO017B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Meatastatic hepatocellular carcinoma (except child Pugh c)\nLiver confined but not suitable for liver directed therapy" ] ], [
fhir:index 81;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO018B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic pancreatic cancer - first line" ] ], [
fhir:index 82;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO018C" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant and adjuvant locally advanced pancreatic cancer" ] ], [
fhir:index 83;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO018E" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Till RT ends\nNeoadjuvant and adjuvant locally advanced pancreatic cancer" ] ], [
fhir:index 84;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO018F" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Pancreatic cancer - adjuvant" ] ], [
fhir:index 85;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO019A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Adjuvant and metastatic gall bladder and cholnagicarcinoma" ] ], [
fhir:index 86;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO019B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant, adjuvant and metastatic pancreatic cancer" ] ], [
fhir:index 87;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO019C" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic gall bladder and cholngiocarcinoma" ] ], [
fhir:index 88;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO019D" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Till RT ends\nDefinitive and Adjuvant therapy in gall bladder cancer" ] ], [
fhir:index 89;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO019E" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metatstatic Gall Bladder Cancer" ] ], [
fhir:index 90;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO020A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant, adjuvant and metastatic GIST" ] ], [
fhir:index 91;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO020B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic GIST" ] ], [
fhir:index 92;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO021A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Adjuvant therapy" ] ], [
fhir:index 93;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO022A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic mesothelioma" ] ], [
fhir:index 94;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO022B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant,adjuvant and metastatic mesothelioma" ] ], [
fhir:index 95;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO023A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant Chemotherapy and metastatic thymic carcinoma" ] ], [
fhir:index 96;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO024A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant and metastatic head and neck squamou cell cancer" ] ], [
fhir:index 97;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO024B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Definitive therapy" ] ], [
fhir:index 98;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO024C" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic squamous cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers" ] ], [
fhir:index 99;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO024D" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant, Metastatic squamou cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers" ] ], [
fhir:index 100;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO024E" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic squamou cell head and neck cancer, salivary gland cancers" ] ], [
fhir:index 101;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO024F" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic Head and neck squamous cell carcinoma" ] ], [
fhir:index 102;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO024G" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant, adjuvant and metastatic esthesioneuroblastoma and Neuroendocrine carcinoma" ] ], [
fhir:index 103;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO024L" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic squamous cell head and neck cancer, salivary gland cancers, nasopharyngeal carcinoma" ] ], [
fhir:index 104;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO024M" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic squamous cell head and neck cancer, salivary gland cancers" ] ], [
fhir:index 105;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO025A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic renal cell carcinoma" ] ], [
fhir:index 106;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO026A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant, Metastatic urothelial cancer" ] ], [
fhir:index 107;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO026B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant, Adjuvant, Metastatic urothelial cancer" ] ], [
fhir:index 108;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO026F" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic urothelial cancer" ] ], [
fhir:index 109;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO027A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant, Adjuvant, Metastatic penile cancer" ] ], [
fhir:index 110;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO027C" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic Penile Cancer" ] ], [
fhir:index 111;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO028A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic prostate cancer" ] ], [
fhir:index 112;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO033A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Multiagent chemotherapy variable in each protocol" ] ], [
fhir:index 113;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO047C" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Optional Vincristine and Prednsiolone\nIntrathecal Methotrexate" ] ], [
fhir:index 114;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO048C" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Optional Vincristine and Prednsiolone, intrathecal Methotrexate" ] ], [
fhir:index 115;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO054A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Histiocytosis Protocol - Induction" ] ], [
fhir:index 116;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO054B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Histiocytosis Protocol - Maintenance" ] ], [
fhir:index 117;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO055A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Low Grade Glioma" ] ], [
fhir:index 118;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO056A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Medulloblastoma" ] ], [
fhir:index 119;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO057A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neuroblastoma" ] ], [
fhir:index 120;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO058A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Retinoblastoma" ] ], [
fhir:index 121;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO059A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Rhabdomyosarcoma" ] ], [
fhir:index 122;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO060A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Relapsed Rhabdomyosarcoma" ] ], [
fhir:index 123;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO062A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Phase II, CNS Therapy Reinduction" ] ], [
fhir:index 124;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO066A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Relapsed Hodgkins Lymphoma" ] ], [
fhir:index 125;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO066B" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Hodgkins Lymphoma" ] ], [
fhir:index 126;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO068A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Non - Hodgkins Lymphoma" ] ], [
fhir:index 127;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO071A" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metstatic non small cell lung cancer - second line" ] ], [
fhir:index 128;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO071E" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic non small cell lung (adenocarcinoma) cancer" ] ], [
fhir:index 129;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO071F" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic small cell lung cancer - second line" ] ], [
fhir:index 130;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO071G" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic Non Small Cell Lung Cancer - in patients unfit for combination therapy" ] ], [
fhir:index 131;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO071H" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant, concurrent with radiation and metastaic small cell lung cancer" ] ], [
fhir:index 132;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO071K" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant and Metastatic Non Small Cell Lung cancer" ] ], [
fhir:index 133;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO071O" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Concurrent chemoradiation in Non Small Cell lung cancer" ] ], [
fhir:index 134;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO071Q" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Neoadjuvant, Adjuvant and Metastatic Non Small Cell Lung cancer (adnocarcinoma and adenosquamous carcinoma)" ] ], [
fhir:index 135;
fhir:ValueSet.expansion.contains.system [ fhir:value "http://hcxprotocol.io/codes/informational-messages-codes" ];
fhir:ValueSet.expansion.contains.code [ fhir:value "MO071R" ];
fhir:ValueSet.expansion.contains.display [ fhir:value "Metastatic non small cell lung cancer (adenocarcinoma) as maintenance after\nCarboplatin + Pemetrexed and\nCisplatin + Pemetrexed 4 -6 cycles" ] ]
].
# - ontology header ------------------------------------------------------------
a owl:Ontology;
owl:imports fhir:fhir.ttl.
IG © 2021+ HCX Open Community. Package hcxprotocol.io#0.7.0 based on FHIR 4.0.1. Generated 2022-11-04
Links: Table of Contents |
QA Report